Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE versus NEXTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE versus NEXTERONE.
DRONEDARONE vs NEXTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
Class III antiarrhythmic agent; prolongs cardiac action potential duration by blocking potassium channels (IKr), primarily affecting the atria and ventricles.
400 mg orally twice daily after meals
Intravenous loading: 150 mg over 10 minutes, then 1 mg/min for 6 hours, followed by maintenance infusion of 0.5 mg/min. Oral: 400 mg twice daily for loading (total 1200 mg/day) for 7-10 days, then maintenance 200-400 mg once daily.
None Documented
None Documented
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
Terminal elimination half-life of 58 days (range 25-110 days) due to extensive tissue distribution and slow release from lipid stores. Steady-state concentrations require approximately 3-6 months of chronic dosing.
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary excretion of metabolites is significant, with approximately 30-40% eliminated in feces. Renal excretion accounts for ~15-20% of total clearance as metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic